about
TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expressionAn update of current treatments for adult acute myeloid leukemiaPrevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Repression of transcription at the human T-cell receptor Vbeta2.2 segment is mediated by a MAX/MAD/mSin3 complex acting as a scaffold for HDAC activity.Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupIn vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 studyNOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia.Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.The European LeukemiaNet: achievements and perspectives.Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.Clofarabine for the treatment of adult acute myeloid leukemia.Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaSite- and allele-specific polycomb dysregulation in T-cell leukaemiaManagement and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursorsRole of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.
P50
Q24315660-F1AACA28-02D5-498C-BA5F-1EE49D335D4DQ26776396-286D7AB8-3B20-4DF5-A3D0-DB337388DA2AQ27824842-D8B778F8-F411-486D-BD7D-793E9A76CFE1Q27851473-F0278142-F1B3-4B85-92D2-8583E679DB0BQ27852997-1BCC26C7-A9AB-49E8-91DD-1697F068238EQ30835785-E06C4D26-AB1B-4F45-A8F4-44D6F028A3DEQ31127163-923C0393-35DF-416E-84F1-49B64FFF2EA5Q31163049-A8242815-FC89-4FC7-A933-78C543A0BBE6Q33185196-53F69858-4D8C-48DA-8898-F238B12F35BDQ33187375-9B24364C-D97A-4400-A296-A4C5A16B4182Q33302879-9FA654C0-033E-4A39-95D4-3B9E27A5FB99Q33368039-D8341B0A-AB77-4DED-AEE1-9F7AC9E1A113Q33392436-C579A34E-C1C4-4ED4-998D-04033628D8C7Q33395926-46AB2947-0D04-426F-A18B-6303903F5369Q33400617-B4410846-910C-4678-8B32-E8AA1F93E4B0Q33572303-A92423E3-29FB-4E52-A957-C9250D4B0ABBQ33574178-AD7BF40C-7276-433F-BE34-F545215D4D5DQ33632278-933A47D1-112A-41CD-9CB4-4B2B8F8283D5Q33741025-E7FEF23A-CFEA-4570-8AD5-45BFFACFA277Q33795018-638CF525-8775-4C92-B891-DBED48B5C104Q33828570-902CE20F-DE75-410F-9249-907623325DE2Q34042800-00DC99EB-A8F2-4D5F-BFE1-5C53EB09F84FQ34088767-4C227E93-2BF1-41D5-B38F-C73C9A1A7A07Q34227693-304B0CBB-FF36-4B45-8EDB-BD9E17F398D2Q34451619-328497B8-31A1-4664-8AFE-1695AB0C91FCQ34543015-93F45931-97DA-49A7-8132-BD753AFB2444Q34577028-BFB10FBC-F89C-4A1F-B8E5-3D10474D32ABQ34584443-128A7804-5C5B-4D7D-9EBA-D18C9695569CQ34615087-EEB617F6-B324-41C7-BDF8-50D501F1BD72Q34627586-610C25E3-0DE4-414B-9637-5CAC0B8F1561Q34638590-598E253E-D020-4B8C-89D5-3924F6FEB4D9Q34646570-3049CCA7-C43F-413D-94B0-B7F6B9899592Q34650186-F4C78499-76C2-421A-B744-8B265AA4E15DQ35009273-F72FF409-B286-4711-A2F7-F0423AA972F0Q35018521-56D6F1D3-CAAA-4D9E-8A08-99DCF3DBFF98Q35050495-1A9C5DEF-9A49-4F9E-8888-28C801E50B34Q35085726-68D91472-3A4C-48C0-B360-10086E97D1C0Q35089575-982E21C5-A2C5-4E87-99FC-FF76CAF872FAQ35214194-9DB786E9-916C-49B4-9F26-25CE6DC53B1CQ35542516-38A0CA5B-B02C-40FE-BC6E-DF4BD30C7E9C
P50
name
Hervé Dombret
@ast
Hervé Dombret
@en
Hervé Dombret
@nl
type
label
Hervé Dombret
@ast
Hervé Dombret
@en
Hervé Dombret
@nl
prefLabel
Hervé Dombret
@ast
Hervé Dombret
@en
Hervé Dombret
@nl
P214
P214
P31
P7859
viaf-24719162